Stifel Lowers Price Target on Outset Medical, Inc. (OM) to $8, Maintains Buy Rating

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. 

On January 7, Stifel analyst Rick Wise lowered the price target on Outset Medical, Inc. (NASDAQ:OM) to $8 from $14 while maintaining a Buy rating on the shares. The adjustment reflects near-term pressures in MedTech following 2025, though the firm remains constructive on the sector overall for 2026.

Outset Medical, Inc. (NASDAQ:OM) continues to demonstrate steady growth in its dialysis solutions business. In Q3 2025, the company reported revenue of $29.4 million, up 3% year-over-year, and raised its 2025 revenue guidance to a range of $115 million to $120 million. Tablo console sales increased 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing in size by more than 20%. These trends underscore Outset’s ability to capture market share and support long-term growth.

Founded in 2003 and headquartered in San Jose, California, Outset Medical, Inc. (NASDAQ:OM) is focused on transforming dialysis, which is one of healthcare’s largest and most expensive segments, through innovative technology, research, and North American manufacturing operations.

While we acknowledge the potential of OM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OM and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.